Search Results - "Tarpgaard, Line S."

What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) by Kryh-Jensen, Charlotte G., Fristrup, Claus W., Ainsworth, Alan P., Detlefsen, Sönke, Mortensen, Michael B., Pfeiffer, Per, Tarpgaard, Line S., Graversen, Martin

“…A definition of long-term survival (LTS) in patients with peritoneal metastasis (PM) from gastric cancer (GC), pancreatic cancer (PC) or colorectal cancer…”
Get full text

RNA expression profiling of peritoneal metastasis from pancreatic cancer treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) by Detlefsen, Sönke, Burton, Mark, Ainsworth, Alan P., Fristrup, Claus, Graversen, Martin, Pfeiffer, Per, Tarpgaard, Line S., Mortensen, Michael B.

“…Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an experimental treatment option in peritoneal metastasis from pancreatic cancer (PM-PC). Aims were…”
Get full text

Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) by Fallah, Mojib, Detlefsen, Sönke, Ainsworth, Alan P., Fristrup, Claus W., Mortensen, Michael B., Pfeiffer, Per, Tarpgaard, Line S., Graversen, Martin

“…Abstract Objectives The four-tiered peritoneal regression grading score (PRGS) is used for histological response evaluation in patients with peritoneal…”
Get full text

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study by Tarpgaard, Line S, Guren, Tormod K, Glimelius, Bengt, Christensen, Ib J, Pfeiffer, Per, Kure, Elin H, Sorbye, Halfdan, Ikdahl, Tone, Yilmaz, Mette, Johansen, Julia S, Tveit, Kjell Magne

“…We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with…”
Get full text

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer by Tarpgaard, Line S, Ørum-Madsen, Maj Sofie, Christensen, Ib J, Nordgaard, Cathrine, Noer, Julie, Guren, Tormod K, Glimelius, Bengt, Sorbye, Halfdan, Ikdahl, Tone, Kure, Elin H, Tveit, Kjell M, Nielsen, Hans J, Pfeiffer, Per, Brünner, Nils, Moreira, José M A

“…It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal…”
Get full text

Quality of life in patients with cancer during the COVID-19 pandemic - a Danish cross-sectional study (COPICADS) by Jeppesen, Stefan S, Bentsen, Kristian K, Jørgensen, Trine L, Holm, Hanne S, Holst-Christensen, Linda, Tarpgaard, Line S, Dahlrot, Rikke H, Eckhoff, Lise

“…The COVID-19 pandemic is an international public health crisis. The risk of getting an infection with COVID-19 might impact the emotional well-being in…”
Get more information

Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance by Jensen, Niels F., Stenvang, Jan, Beck, Mette K., Hanáková, Barbora, Belling, Kirstine C., Do, Khoa N., Viuff, Birgitte, Nygård, Sune B., Gupta, Ramneek, Rasmussen, Mads H., Tarpgaard, Line S., Hansen, Tine P., Budinská, Eva, Pfeiffer, Per, Bosman, Fred, Tejpar, Sabine, Roth, Arnaud, Delorenzi, Mauro, Andersen, Claus L., Rømer, Maria U., Brünner, Nils, Moreira, José M.A.

“…Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or…”
Get full text

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification by Tarpgaard, Line S, Qvortrup, Camilla, Nygård, Sune B, Nielsen, Signe L, Andersen, Diana R, Jensen, Niels Frank, Stenvang, Jan, Detlefsen, Sönke, Brünner, Nils, Pfeiffer, Per

“…The overall purpose of this study is to provide proof of concept for introducing the anthracycline epirubicin as an effective, biomarker-guided treatment for…”
Get full text

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer by Rasmussen, Mads H., Jensen, Niels F., Tarpgaard, Line S., Qvortrup, Camilla, Rømer, Maria U., Stenvang, Jan, Hansen, Tine P., Christensen, Lise L., Lindebjerg, Jan, Hansen, Flemming, Jensen, Benny V., Hansen, Torben F., Pfeiffer, Per, Brünner, Nils, Ørntoft, Torben F., Andersen, Claus L.

“…The backbone of current cytotoxic treatment of metastatic colorectal cancer (mCRC) consists of a fluoropyrimidine together with either oxaliplatin…”
Get full text

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab by Boisen, Mogens K, Dehlendorff, Christian, Linnemann, Dorte, Nielsen, Boye S, Larsen, Jim S, Osterlind, Kell, Nielsen, Svend E, Tarpgaard, Line S, Qvortrup, Camilla, Pfeiffer, Per, Holländer, Niels H, Keldsen, Nina, Hansen, Torben F, Jensen, Brita B, Høgdall, Estrid V S, Jensen, Benny V, Johansen, Julia S

“…We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin…”
Get full text

The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer by Lin, Xue, Stenvang, Jan, Rasmussen, Mads Heilskov, Zhu, Shida, Jensen, Niels Frank, Tarpgaard, Line S, Yang, Guangxia, Belling, Kirstine, Andersen, Claus Lindbjerg, Li, Jian, Bolund, Lars, Brünner, Nils

“…Irinotecan (SN38) and oxaliplatin are chemotherapeutic agents used in the treatment of colorectal cancer. However, the frequent development of resistance to…”
Get full text

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab by Tarpgaard, Line S., Christensen, Ib J., Høyer‐Hansen, Gunilla, Lund, Ida K., Guren, Tormod K., Glimelius, Bengt, Sorbye, Halfdan, Tveit, Kjell M., Nielsen, Hans Jørgen, Moreira, José M. A., Pfeiffer, Per, Brünner, Nils

“…Circulating forms of the urokinase plasminogen activator receptor (uPAR) are associated with prognosis in patients with colorectal cancer. Preclinical studies…”
Get full text

Abstract 2927: miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cell by Rasmussen, Mads H., Lyskjær, Iben, Jersie-Christensen, Rosa R., Tarpgaard, Line S., Primdal-Bengtson, Bjarke, Nielsen, Morten M., Pedersen, Jakob S., Hansen, Tine P., Hansen, Flemming, Olsen, Jesper V., Pfeiffer, Per, Ørntoft, Torben F., Andersen, Claus L.

“…Abstract Oxaliplatin (oxPt) resistance in colorectal cancers (CRC) is a major medical problem, and predictive markers are urgently needed. Recently, miR-625-3p…”
Get full text

Abstract 1157: MicroRNA-625-3p is associated with response to first-line oxaliplatin-based treatment of metastatic colorectal cancer by Rasmussen, Mads H., Jensen, Niels F., Tarpgaard, Line S., Qvortrup, Camilla, Rømer, Maria U., Stenvang, Jan, Hansen, Tine P., Christensen, Lise-Lotte, Lindebjerg, Jan, Hansen, Flemming, Jensen, Benny V., Hansen, Torben F., Jakobsen, Anders M., Pfeiffer, Per, Brünner, Nils, Ørntoft, Torben F., Andersen, Claus L.

“…Abstract The backbone of current oncologic treatment of metastatic colorectal cancer (mCRC) consists of fluoropyrimidine together with either oxaliplatin…”
Get full text